Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Phase 1

Terminated

Conditions: Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma

Interventions: Biological: brexucabtagene autoleucel
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2018-08-09

Last Posted Date: 2023-11-18

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 16

Registration Number: NCT03624036

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇮🇹
IRCCS Ospedale San Raffaele, Milano, Italy
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 19 locations

E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: EGFR-TK Inhibitor
Biological: EGF-PTI
Drug: Cyclophosphamide

First Posted Date: 2018-08-09

Last Posted Date: 2022-06-30

Lead Sponsor: Instituto Oncológico Dr Rosell

Target Recruit Count: 23

Registration Number: NCT03623750

Locations: 🇪🇸
Instituto Oncológico Dr. Rosell, Barcelona, Spain
🇪🇸
Hospital Clínic Barcelona, Barcelona, Spain
🇪🇸
Hospital Universitario Regional de Málaga, Málaga, Spain

and more 1 locations

Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients

Phase 2

Conditions: Experimental Tumor

Interventions: Drug: Chidamide
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Etoposide
Drug: Prednisone

First Posted Date: 2018-08-06

Last Posted Date: 2018-09-04

Lead Sponsor: Peking University

Target Recruit Count: 114

Registration Number: NCT03617432

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Phase 2

Terminated

Conditions: Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Acute Lymphoid Leukemia (ALL)
Chronic Myeloid Leukemia (CML)
Hodgkin Lymphoma
Acute Myeloid Leukemia (AML)

Interventions: Radiation: Hyperfractionated total body irradiation
Drug: Busulfan
Drug: Thiotepa
Drug: Fludarabine
Drug: Melphalan
Drug: Cyclophosphamide
Drug: Clofarabine
Procedure: HPC(A) stem cell allograft
Drug: Rituximab
Device: Rabbit antithymocyte globulin

First Posted Date: 2018-08-03

Last Posted Date: 2024-03-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 9

Registration Number: NCT03615105

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

Phase 1

Terminated

Conditions: Peritoneal Mesothelioma
Adenocarcinoma of the Ovary
Primary Peritoneal Carcinoma
Fallopian Tube Adenocarcinoma

Interventions: Biological: MCY-M11
Drug: Cyclophosphamide

First Posted Date: 2018-08-01

Last Posted Date: 2021-09-05

Lead Sponsor: MaxCyte, Inc.

Target Recruit Count: 14

Registration Number: NCT03608618

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States
🇺🇸
Washington University at St. Louis, Saint Louis, Missouri, United States

and more 1 locations

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Phase 2

Terminated

Conditions: Platinum-Resistant Ovarian Carcinoma
Recurrent High Grade Ovarian Serous Adenocarcinoma
Refractory Colorectal Carcinoma
Malignant Solid Neoplasm
Metastatic Colorectal Adenocarcinoma
Metastatic Pancreatic Ductal Adenocarcinoma
Stage IV Colorectal Cancer AJCC v8
Stage IVC Colorectal Cancer AJCC v8
Metastatic Ovarian Carcinoma
Recurrent Ovarian Carcinosarcoma

Interventions: Biological: Autologous Tumor Infiltrating Lymphocytes MDA-TIL
Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Interleukin-2
Other: Quality-of-Life Assessment

First Posted Date: 2018-08-01

Last Posted Date: 2024-08-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT03610490

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation

Phase 2

Withdrawn

Conditions: Chronic Myelomonocytic Leukemia
Myelodysplastic Syndrome
Myelofibrosis
Recurrent Hodgkin Lymphoma
Therapy-Related Acute Myeloid Leukemia
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Hematopoietic and Lymphoid System Neoplasm
Acute Lymphoblastic Leukemia in Remission
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Recurrent Non-Hodgkin Lymphoma

Interventions: Biological: Anti-Thymocyte Globulin
Drug: Busulfan
Drug: Cyclophosphamide
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Drug: Methotrexate
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2018-07-27

Last Posted Date: 2021-06-30

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT03602898

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Myeloma-Multiple
Myeloma, Plasma-Cell

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells

First Posted Date: 2018-07-27

Last Posted Date: 2024-11-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT03602612

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia

Phase 2

Terminated

Conditions: Myelodysplastic Syndrome (MDS)
Acute Myelogenous Leukemia (AML)
Fanconi Anemia

Interventions: Drug: Busulfan
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Anti-Thymocyte Globulin (Rabbit)
Device: The CliniMACS device
Drug: G-CSF

First Posted Date: 2018-07-26

Last Posted Date: 2022-04-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT03600909

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Phase 1

Active, not recruiting

Conditions: Ewing Sarcoma
Clear Cell Sarcoma
Myoepithelial Tumor
Desmoplastic Small Round Cell Tumor
Angiomatoid Fibrous Histiocytoma
Myxoid Liposarcoma
Sarcoma,Soft Tissue
Extraskeletal Myxoid Chondrosarcoma
Sclerosing Epithelioid Fibrosarcoma
Fibromyxoid Tumor

Interventions: Drug: Seclidemstat
Drug: Cyclophosphamide
Drug: Topotecan

First Posted Date: 2018-07-26

Last Posted Date: 2023-11-21

Lead Sponsor: Salarius Pharmaceuticals, LLC

Target Recruit Count: 50

Registration Number: NCT03600649

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States

and more 12 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy